althiomycin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
althiomycin : A peptide antibiotic isolated from soil and enteric bacteria. It is a protein synthesis inhibitor which exhibits antibacterial activity against both Gram-positive and Gram-negative bacteria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 135488978 |
| CHEMBL ID | 152828 |
| MeSH ID | M0055237 |
| Synonym |
|---|
| NSC102809 , |
| 12656-40-5 |
| althiomycin |
| CHEMBL152828 |
| AKOS040746546 |
Althiomycin is a ribosome-inhibiting antibiotic. Its biosynthetic machinery had been elusive for decades.
| Excerpt | Reference |
|---|---|
| "Althiomycin is a ribosome-inhibiting antibiotic whose biosynthetic machinery had been elusive for decades." | ( The insect pathogen Serratia marcescens Db10 uses a hybrid non-ribosomal peptide synthetase-polyketide synthase to produce the antibiotic althiomycin. Challis, GL; Coulthurst, SJ; Gerc, AJ; Song, L; Stanley-Wall, NR, 2012) |
| Role | Description |
|---|---|
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| antibacterial agent | A substance (or active part thereof) that kills or slows the growth of bacteria. |
| protein synthesis inhibitor | A compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 1,3-thiazoles | |
| gamma-lactam | A lactam in which the amide bond is contained within a five-membered ring, which includes the amide nitrogen and the carbonyl carbon. |
| aldoxime | Oximes of aldehydes RCH=NOH. |
| pentapeptide | Any molecule that contains five amino-acid residues connected by peptide linkages. |
| tertiary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2). |
| secondary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). |
| primary alcohol | A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. |
| ether | An organooxygen compound with formula ROR, where R is not hydrogen. |
| pyrroline | Any organic heteromonocyclic compound with a structure based on a dihydropyrrole. |
| peptide antibiotic | A chemically diverse class of peptides that exhibit antimicrobial properties. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID69824 | Tested for the minimum inhibitory concentration against Escherichia coli 1852E + 3 ug/mL PMBN | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin. |
| AID206194 | Tested for the minimum inhibitory concentration against Staphylococcus aureus 853E | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin. |
| AID202540 | Tested for the minimum inhibitory concentration against Saccharomyces cerevisiae NCYC 81 | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin. |
| AID206315 | Tested for the minimum inhibitory concentration against Staphylococcus aureus col | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin. |
| AID69825 | Tested for the minimum inhibitory concentration against Escherichia coli 1852E PM | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin. |
| AID40924 | Tested for the minimum inhibitory concentration against Bacillus subtilis 6633 | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin. |
| AID208463 | Tested for the minimum inhibitory concentration against Streptococcus pneumoniae 3512 | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin. |
| AID66381 | Tested for the minimum inhibitory concentration against Enterobacter faecalis 850E | 2002 | Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4 | Total synthesis and semi-synthetic approaches to analogues of antibacterial natural product althiomycin. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||